The Claim
In adults with obesity and prediabetes, treatment with liraglutide is associated with a small but significant reduction in lean body mass, while caloric restriction is associated with preservation of lean body mass, despite comparable total weight loss between the two interventions.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity and prediabetes, liraglutide treatment leads to a small loss of lean body mass, while caloric restriction maintains lean body mass, even when both approaches result in the same amount of total weight loss.
See the scientific wording
In adults with obesity and prediabetes, liraglutide treatment is associated with a small but significant loss of lean body mass, whereas caloric restriction preserves lean mass, suggesting differential effects on tissue composition despite similar weight loss goals.
When the GLP-1 receptor is activated, the body reduces its use of fat for energy and instead breaks down muscle tissue to meet energy needs, even when food intake doesn't drop much. This causes muscle loss during weight loss, while eating less without the drug lets the body use fat instead and keeps muscle intact.
What the research says
1 studyWhen people with obesity and prediabetes lost weight by eating less, they kept more muscle than those who took liraglutide, even though both groups lost weight. So the drug didn’t protect muscle as well as dieting did.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.